Find the online form for feedback on Pharmac's website here:
https://www.pharmac.govt.nz/news-and-resources/consultations-and-decisions/2026-01-proposal-to-widen-access-to-trikafta-and-kalydeco-and-fund-alyftrek-for-the-treatment-of-cystic-fibrosis

A guide to help you through the feedback process:

PROPOSAL TO WIDEN ACCESS TO TRIKAFTA AND KALYDECO AND FUND ALYFTREK FOR THE TREATMENT OF CYSTIC FIBROSIS

I/We strongly support Pharmac's proposal to fund new treatment options for people living with cystic fibrosis (CF) with eligible mutations, including young children, from 1 April 2026.

I/We strongly support Phramc's proposal to:

- Widen access to Trikafta (elexacaftor/tezacaftor/ivacaftor)r and Kalydeco (ivacaftor) for all people with eligible mutations
- Fund a new treatment, Alyftrek (vanzacaftor/tezacaftor/deutivacaftor).

Benefits of and Support for Widening Access to Trikafta

Trikafta is the first medicine to treat the underlying cause of CF for the majority of people with this devastating and life-limiting condition. Widening access to include all people with eligible mutations will:

- Bring life-changing benefits to eligible young children, while easing the emotional burden on families, and giving them a future to look forward to.
- Reset the trajectory of our young ones' lives. Intervening early will spare children from severe illness and help to prevent life-long, irreparable damage.
- Reduce pressure on the health system through fewer treatments, hospital stays, and lung transplants.
- Enable families with young children with CF to stay in New Zealand and provide the potential to reunite families who have already gone overseas to access Trikafta.
- Enable Trikafta to be used as soon as clinically appropriate, regardless of age.

The CF community has already demonstrated to Pharmac that there is overwhelming support of funding Trikafta for young children in New Zealand by:

- Submitting over 70 heartfelt and emotive letters from parents, caregivers, relatives, friends, clinicians, and other CF organisations demonstrating the social, financial, and emotional impacts of living with CF.

Why is funding Trikafta important to me/my family?

If you are happy to share a personal story, please say why funding Trikafta is important to you e.g. what benefits would it bring, what impact would it have on you, your family, and your day-to-day life.

Benefits of and Support for Widening Access to Kalydeco and Funding Alyftrek

Every Kiwi with CF needs access to a life-changing medicine that treats the cause of this devastating and life-shortening condition. While Trikafta will benefit the majority of people with CF in New Zealand, there are some for whom it will not be a suitable option.

Widening access to Kalydeco and making Alyftrek available will provide more treatment options for people with CF.

Why is widening access to Kalydeco and/or having access to Alyftrek important to me/my family?

If you are happy to share a personal story, please say why widening access to Kalydeco or funding Alyftrek is important to you e.g. what benefits would it bring, what impact would it have on you, your family, and your day-to-day life.

Include your name and contact details below